Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo

  title={Evaluation of sigma ($\sigma$) receptors in the antidepressant-like effects of ketamine in vitro and in vivo},
  author={Matthew J Robson and Meenal Elliott and Michael J. Seminerio and Rae R. Matsumoto},
  journal={European Neuropsychopharmacology},
The Involvement of Sigma Receptor Modulation in the Antidepressant Effects of Ketamine and the Neurotoxic Actions of Methamphetamine
Data suggest that sigma receptor-mediated neuronal remodeling may contribute to the antidepressant effects of ketamine.
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Data suggest that dextromethorphan exerts some of its antidepressant actions through σ1 receptors, which has been hypothesized to display rapid-acting antidepressant activity based on pharmacodynamic similarities to the N-methyl-D-aspartate receptor antagonist ketamine.
Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice
Behavioral and biochemical analyses were carried out to evaluate the potential involvement of brain-derived neurotrophic factor (BDNF) in the antidepressant-like effects of DM in mice, and data show that DM shares some features with both ketamine and imipramine.
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Pharmacological target deconvolution of ketamine and its metabolites will provide insight critical to the development of new pharmacotherapies that possess the desirable clinical effects of ketamines, but limit undesirable side effects.
A Selective M1 and M3 Receptor Antagonist, Penehyclidine Hydrochloride, Exerts Antidepressant-Like Effect in Mice
The findings suggest that PHC, an anti-muscarinic drug in clinical use, elicits rapid onset antidepressant-like effect, shedding light on the development of new antidepressants.
Ketamine: The final frontier or another depressing end?
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
This work aims to be a reference for psychiatrists who may soon be faced with the possibility of prescribing psychedelic compounds as medications, helping them assess which compound(s) and regimen could be most useful for decreasing specific psychiatric symptoms.


Novel sigma (σ) receptor agonists produce antidepressant-like effects in mice
Pharmacological interaction with the sigma1 (σ1)-receptor in the acute behavioral effects of antidepressants.
The behavioral effects induced by mixed σ(1)-receptor/SSRI antidepressants, like fluvoxamine or sertraline, may involve a non-selective action at both targets, and the CFS appears to more reliably uncover a �o(1) pharmacological component in antidepressant screening.
Potential antidepressant activity of sigma ligands.
  • G. Skuza
  • Biology, Psychology
    Polish journal of pharmacology
  • 2003
A potential antidepressant activity of sigma1 receptor agonists has been postulated, since the antidepressive-like actions of these compounds have been shown in animal models.
A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors.
Igmesine, OPC-14 523 and SA4503, have recently been developed as sigma-1 agonists and are found to have antidepressant-like activity perhaps with fewer side effects, suggesting a role of antidepressants in neuroplasticity.
Interaction of the chiral forms of ketamine with opioid, phencyclidine, σ and muscarinic receptors
The analgesic effect of ketamine in humans is most probably mediated via phencyclidine receptors, although a kappa effect can not be excluded.
Modulation of serotonergic neurotransmission by short‐ and long‐term treatments with sigma ligands
A modulation of serotonergic neurotransmission by some sigma receptors is suggested and a potential mechanism for the ‘antidepressant effects’ reported is provided and evidence is provided toward sigma1 ligands as potential antidepressants with a rapid onset of action.
Interaction of ketamine with μ2 opioid receptors in SH-SY5Y human neuroblastoma cells
The present study indicates that a clinically relevant concentration of ketamine interacts with μ2 opioid receptors, however, no agonist activity was observed.